vTv Therapeutics Inc (NASDAQ:VTVT) major shareholder Ronald O. Perelman acquired 1,212,121 shares of the firm’s stock in a transaction dated Tuesday, June 25th. The stock was bought at an average price of $1.65 per share, for a total transaction of $1,999,999.65. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.
vTv Therapeutics stock opened at $1.43 on Thursday. The firm has a market cap of $67.93 million, a price-to-earnings ratio of -2.07 and a beta of -3.70. vTv Therapeutics Inc has a 52-week low of $0.68 and a 52-week high of $6.09. The business’s 50 day simple moving average is $1.53.
vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported ($0.26) earnings per share for the quarter. The firm had revenue of $0.92 million for the quarter. On average, analysts anticipate that vTv Therapeutics Inc will post -0.59 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently bought and sold shares of VTVT. Barclays PLC raised its holdings in shares of vTv Therapeutics by 366.7% during the fourth quarter. Barclays PLC now owns 28,000 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 22,000 shares during the period. D. E. Shaw & Co. Inc. acquired a new stake in shares of vTv Therapeutics during the fourth quarter worth $186,000. Finally, Wedbush Securities Inc. acquired a new stake in shares of vTv Therapeutics during the first quarter worth $30,000. 3.94% of the stock is currently owned by hedge funds and other institutional investors.
vTv Therapeutics Company Profile
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.
Featured Article: Trade Deficit
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.